07/29/2026
👏👏👏
The Lewy Body Dementia Association (LBDA) is proud to announce a $2.5 million grant to the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at UT Health San Antonio to lead Clin-Syn, a national, multi-site study designed to advance the detection and diagnosis of dementia with Lewy bodies (DLB).
“Clin-Syn is more than a biomarker study; it is a strategic investment in the evidence infrastructure the Lewy body dementia field urgently needs. By determining what emerging alpha-synuclein tests actually measure, how they relate to symptoms and coexisting Alzheimer’s pathology, and how they can be used in real-world clinical and research settings, this initiative can help move us from diagnostic uncertainty toward earlier, more precise diagnosis and better-designed clinical trials. Most importantly, it brings us closer to a future in which people living with Lewy body dementia can be identified sooner and matched to the right care and, ultimately, the right treatments.” — Sudhir Sivakumaran, PhD, Chief Scientific Officer, LBDA.
Clin-Syn will evaluate multiple emerging alpha-synuclein biomarker tests alongside Alzheimer’s disease biomarkers, clinical symptoms and participant perspectives. The study will enroll 125 participants across four expert research centers: UT Health San Antonio, the University of Florida, the University of California San Francisco and Virginia Commonwealth University.
The project will also create a high-quality, open-access repository of biological samples and clinical data to support future biomarker validation, diagnostic research and therapeutic development in DLB.
This landmark initiative reflects LBDA’s commitment to tackling the practical barriers that have slowed progress in LBD: diagnostic uncertainty, limited biomarker validation, mixed disease pathology and the need for more precise, trial-ready patient populations.
Learn more about Clin-Syn: https://ow.ly/gEV950Zut04